Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Quest Diagnostics Incorporated

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term

DGX teams up with Epic on Project Nova to streamline lab testing, boost efficiency, and enhance patient and provider experiences.

Quest Diagnostics Joins Forces With Epic to Improve Laboratory Testing

Quest Diagnostics' Haystack Oncology joins Rutgers Cancer Institute to study how its ctDNA MRD test can guide therapy for stage II/III lung cancer.

DGX's Haystack Oncology Teams Up With Rutgers Cancer Institute

Quest Diagnostics Incorporated (NYSE:DGX ) Jefferies 2025 Healthcare Services Conference September 29, 2025 4:35 PM EDT Company Participants Sam Samad - Executive VP & CFO Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division Okay, we're going to kick it off. I'm Tycho Peterson from the life science team at Jefferies.

Quest Diagnostics Incorporated (DGX) Presents at Jefferies 2025 Healthcare Services Conference Transcript

SECAUCUS, N.J. , Sept. 25, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report third quarter 2025 financial results on Tuesday, October 21, 2025, before the market opens.

Quest Diagnostics to Release Third Quarter 2025 Financial Results on October 21, 2025

An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, DVA, ADUS and PNTG are well-poised to gain.

4 Outpatient Home Health Stocks Worth Watching Amid Shifting Trends

PALO ALTO, Calif. & SECAUCUS, N.J.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a broad strategic collaboration to make Guardant's Shield™ blood-based screening test available to physicians and patients served by Quest in the United States. Shield is the first and only blood test to receive full FDA approval as a primary screening option for colorectal c.

Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield™ Blood-based Screening Test in the United States

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

With the most comprehensive Epic integration by a laboratory provider, collaboration will streamline and strengthen the customer experience for health systems, hospitals, independent providers and their patients SECAUCUS, N.J. , Sept. 23, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX) and Epic today announced a first-of-its-kind collaboration designed to streamline and improve experiences for healthcare providers and patients that engage Quest for laboratory testing in the United States.

Quest Diagnostics to Improve Laboratory Testing Experience with Industry-First Epic Collaboration

DGX posts strong gains from physician and hospital channels while advancing AI-powered solutions.

Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now?

Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer

BOSTON--(BUSINESS WIRE)--WHOOP, the human performance company, today announced that Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will be the U.S. lab provider for WHOOP Advanced Labs, a new WHOOP feature that provides laboratory insights supporting health and performance. The offering will provide the option to purchase Quest's clinical laboratory testing, schedule an appointment for testing, and receive test results within the WHOOP app. WHOOP Advanced.

WHOOP to Bring Clinical Lab Testing from Quest Diagnostics to the WHOOP App

SECAUCUS, N.J. , Sept. 15, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during the Jefferies Healthcare Services Conference in Nashville on Monday, September 29, 2025, at 4:35 p.m.

Quest Diagnostics to Speak at the Jefferies Healthcare Services Conference

Quest Diagnostics Incorporated (NYSE:DGX ) Baird Global Healthcare Conference 2025 September 10, 2025 10:50 AM EDT Company Participants James Davis - Chairman, CEO & President Conference Call Participants Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division Presentation Eric Coldwell Senior Research Analyst Thanks, everyone, for joining us.

Quest Diagnostics Incorporated (DGX) Presents At Baird Global Healthcare Conference 2025 Transcript

Explore the exciting world of Quest Diagnostics (DGX 0.35%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

Quest Diagnostics: A Solid Investment or a Risky Bet?

New Service Empowers Clinicians with Personalized Insights from Coriell Life Sciences to Optimize Prescribing Across Specialties SECAUCUS, N.J. , Sept. 4, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced an advanced pharmacogenomic (PGx) laboratory test service designed to help providers understand the patient's individual genetic response to select drug therapies.

Quest Diagnostics Launches Advanced Pharmacogenomics (PGx) Offering

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term

Majority of fentanyl positives also contain other drugs, with co-positivity with marijuana doubling since 2020 SECAUCUS, N.J. , Sept. 2, 2025 /PRNewswire/ -- The percentage of employees in the general U.S. workforce testing positive for fentanyl in random drug tests far exceeded those in pre-employment testing, according to the 2025 Quest Diagnostics Drug Testing Index™ from Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services.

Fentanyl Positivity Is More Than Seven Times Higher in Random Tests vs. Pre-Employment Drug Screening, Finds 2025 Quest Diagnostics Drug Testing Index

Quest Diagnostics (DGX) is a Top-Ranked Momentum Stock: Should You Buy?

Quest Diagnostics shares rise after forming a joint venture with Corewell Health to expand advanced lab services across Michigan.

DGX Stock Gains Following a New Joint Venture With Corewell Health

Real-time stock quote and overview for DGX